CTLA-4?÷ê½üÃêÃÃÃöÃâÃÃÃÃÃÃÃìÃòµÃÃ÷Ã÷ÃÃã¬ÃÃÃÃÃöÃâÃÃÃÃÃÃÃìÃòÃö³öÃôó¹±Ãá£IpilimumabÃ÷êÃðÃñÃÃé¹ó±¦¹«Ã¾¿ª·¢µÃµÃû¸ö»ñµÃFDAÃ
úüÃÃÃõÃCTLA-4µ¥¿¹£¬ÃäûÃÃÃô²ÃûñµÃÃþôóµÃ³Ã¹¦£¬µ«Ã²°éÃæÃÃ
ÿÃõÃÃâÃÃÃÃÃÃÃà ¹Ã²»Ã¼Ãüþ£¨severe immunotherapy-related adverse events£¬irAEs£©¡£ÃùúÃÃÃïü´óçÃõÃô½ÃÃÿÃÃâÃéÃÃ𿪷¢µÃ°ÃÃòCTLA-4ÃÃÃÃÃÿ¹ÃÃ¥ÃÃáÃóãÃÃÃÃÃà ±ÃIpilimumabÃÃþ³ö¸üÃõÃirAEs¡¢¸üÿµÃÃÃÃöÃéïTregø°ûºÃ½ÃÃü°¿¹ÃÃÃöÃÃæ¡£ÃªÃøüºÃµÃÃýâ¸ÃCTLA-4ÃÃÃÃÃÿ¹ÃåµÃÃ÷ÃûúÃÃÃü°µÃ¸±Ã÷Ãã¬ÃÃúñ¼·Ã½ÃÃÿÃÃâÃéÃëÃõÃô½ÃÃá¢Ãú£½»Ã¨´óçýçúÃð®ÃäÃþ¿Ã±¿ÃÃâÃ鹲üÃÃ÷ý¾¿Ãøÿ¹Ã壨HL32£©Ã÷ÃÃÃÃCTLA-4µÃ½á¹¹»úÃá£
Â
    Ã¨¹ý½âÃöHL32-FabºÃÃöþ¾ÃÃÃ¥CTLA-4µÃ¸´ºÃÃï¾§Ãå½á¹¹£¨·Ã±æÃÃ3.05 Ã
£©£¬ÃûÃÃ¥ÃÃþ³öý¸öµ¥¶ÃµÃHL32-Fab·Ã±ð´¹Ã񫠧ÃÃÃCTLA-4öÃë¿çÃ¤Ãø¶Ã¡£HL32-FabÃ÷êè¹ý³¤¦Ã·¢¼ÃôµÃÃÃôCDR3½á¹¹ÃòÃëCTLA-4ð¦Ãì²ãµÃ²¿£¨strands A¡¢GºÃFG loop£©ÃÃû¸öÃÃ6¸öÃð±ÃáÃé³ÃµÃ¾Ã´óÃèî½áºÃÃæÃà »¥Ã÷Ãá£ÃâÃëðÃñ¨µÃµÃIpilimumabºÃCTLA-4Ã÷êÃÃÃâ¼üê»ù´¡µÃÃà »¥Ã÷ÃôæÃþôó²îÃì¡£½øÃ»²½µÃ½áºÃÃ÷ÃÃÃæ·ÃÃö·¢Ãã¬ÃëB7Ã
äÃåºÃÃäÃû¿¹Ãå½áºÃ±Ãû²»Ã¬£¬HL32Ã÷ê½áºÃÃÃCTLA-4öÃë¿çÃ¤ÃøµÃÃÃ²à µÃ¶Ã£¬¸Ã½áºÃÃøÃòÃäöÃëÃäÃû¿¹ÃåµÃÃýÃæ½áºÃ£¬µ«ÃÃû´æÃúÃB7Ã
äÃå±Ãû½áºÃ¾ºÃù¹ÃÃ未Ãò´Ã¸Ã¿¹ÃåêCTLA-4Ãè¶ÃÃÿ¹Ãå¡£ÃýâCTLA-4µÃÃúÃù¦ÃõÃÃõãÃ÷êÃÃCTLA-4Ãæ¼°µÃÃé³ÃÃÃû·²¢½éµ¼B7µÃÃÃÃÃÃ÷Ã㬲»ÃµÃ¿¹Ãå½áºÃCTLA-4¶ÃÃäÃÃû·²úÃúµÃ²»Ã¬Ã°Ãì¿ÃÃÃÃÿ¹Ãå²úÃú¶¾ÃõÃÃ÷êÃòÃã¬Ãð®ÃäÃþ¿ÃÃ
¶Ãîð·¢ÃÃIpilimumabðÃìÃÃCTLA-4´Ãø°ûÃÃÃòø°û±ÃÃæµÃû·ÃµÃ³£¬²¢½øÃëÃÃøÃå½µ½âþ¾¶¡£±¾Ãþ¿Ã÷¢ÃÃHL32è¹ýÃÃÃÃøÃåµÃÃáÃû·¾³ÃÃÃëCTLA-4ÃÃçµÃ½âÃ룬Ãò±£³ÃÃÃCTLA-4¼ÃÃøÃòø°û±ÃÃ涨ûµÃû·»úÃ᣾§ÃåçµÃ·ÃÃöÃîÃýâÃÃÃÃÃâûÃÃÃóµÃ·ÃÃûúÃ㬼´ÃÃCTLA-4ºÃHL32µÃ½áºÃ½çÃ渽½ü´æÃÃÃøöÃé°±Ãá²Ã»ù£¬pHµÃ±ä»¯¿ÃÃÃȇðÃìÃâéÃé°±Ãá²Ã»ùµÃÃäÃò»·µÃ懧Ãôã«Ã¶øµ¼Ãþò¿Ãà »¥Ã÷ÃøÃ񄜪ÃÃ
ÃÃHL32ÃëCTLA-4î¼äµÃ½áºÃÃà »¥Ã÷Ãá£
Â
    ¸ÃÃþ¿Ãá°Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody¡±ÃªÃ⣬ÃÃ2020Ãê11ÃÃ3ÃÃÃÃCell DiscoveryÃÃÃ÷¢±Ã¡£±±¾©Ã¦·¶´óçÃúÃü¿Ãççú²©Ã¿Ãþ¿Ãú¸ÃìÃêµÃûÃ÷Ãã¬ñ¼·Ã½ÃÃá¢ÃõÃô½ÃÃúÃÃú£½»Ã¨´óçýçúÃð®ÃäÃþ¿Ã±Ãª¹²Ã¬Ã¨Ã¶Ã÷Ãá£
Â
    ÃÂÃÃô½Ã£ºhttps://www.nature.com/articles/s41421-020-00202-9
Â
版权与免责声明:本网页的内容由收集互联网上公开发布的信息整理获得。目的在于传递信息及分享,并不意味着赞同其观点或证实其真实性,也不构成其他建议。仅提供交流平台,不为其版权负责。如涉及侵权,请联系我们及时修改或删除。邮箱:sales@allpeptide.com